Posted 10/18/2022 5:48 AM (GMT -8)
Hi, just wanted to point out that the UK is still part of Europe 😁
Apart from that, jyseleca is similar to rinvoq (upadacitinib) in that they are both JAK-1 inhibitors.
Xeljanz, the first JAK-inhibitor to be licensed for UC, inhibits both JAK-1 and JAK-3.
In being more targeted, it is probable that jyseleca and rinvoq are both safer and more effective than xeljanz. More data on this will become available in time.
That being said, all 3 drugs are particularly effective in patients who have failed to respond to biologics and other treatments. Since most people who take these drugs do so as a "last resort" it's hard to know whether these drugs are more effective for all UC patients or whether it's to do with blocking a particular immune pathway that's important in a subtype of UC.
Either way, yes many of us have had great success on these drugs, often when we had run out of other medical options. And they work FAST as well (can usually notice changes in the first week)